menu
    • menu
    [{"orgOrder":0,"company":"Peking Union Medical College Hospital","sponsor":"Techpool Bio-Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Urinastatin","moa":"enzyme inhibitors: antihyperlipidemics (HMG-CoA inhibitors)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Peking Union Medical College Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking Union Medical College Hospital \/ Techpool Bio-Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Peking Union Medical College Hospital \/ Techpool Bio-Pharma"},{"orgOrder":0,"company":"Techpool Bio-Pharma","sponsor":"Peking Union Medical College Hospital | Wuhan Union Hospital | First Clinical College of Harbin Medical University | The First Affiliated Hospital with Nanjing Medical University | West China Hospital | First Affiliated Hospital, Sun Yat-Sen University","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Urinastatin","moa":"enzyme inhibitors: antihyperlipidemics (HMG-CoA inhibitors)","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase IV","graph3":"Techpool Bio-Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Techpool Bio-Pharma \/ Peking Union Medical College Hospital | Wuhan Union Hospital | First Clinical College of Harbin Medical University | The First Affiliated Hospital with Nanjing Medical University | West China Hospital | First Affiliated Hospital, Sun Yat-Sen University","highestDevelopmentStatusID":"11","companyTruncated":"Techpool Bio-Pharma \/ Peking Union Medical College Hospital | Wuhan Union Hospital | First Clinical College of Harbin Medical University | The First Affiliated Hospital with Nanjing Medical University | West China Hospital | First Affiliated Hospital, Sun Yat-Sen University"},{"orgOrder":0,"company":"Techpool Bio-Pharma","sponsor":"Shanghai Children's Medical Center | Guangzhou Women and Children's Medical Center | Guangzhou General Hospital of Guangzhou Military Command | Nanjing Children's Hospital | Children's Hospital of Fudan University","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Urinastatin","moa":"enzyme inhibitors: antihyperlipidemics (HMG-CoA inhibitors)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Techpool Bio-Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Techpool Bio-Pharma \/ Shanghai Children's Medical Center | Guangzhou Women and Children's Medical Center | Guangzhou General Hospital of Guangzhou Military Command | Nanjing Children's Hospital | Children's Hospital of Fudan University","highestDevelopmentStatusID":"11","companyTruncated":"Techpool Bio-Pharma \/ Shanghai Children's Medical Center | Guangzhou Women and Children's Medical Center | Guangzhou General Hospital of Guangzhou Military Command | Nanjing Children's Hospital | Children's Hospital of Fudan University"},{"orgOrder":0,"company":"Techpool Bio-Pharma","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Urinastatin","moa":"enzyme inhibitors: antihyperlipidemics (HMG-CoA inhibitors)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Techpool Bio-Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Techpool Bio-Pharma \/ The First Affiliated Hospital of Guangzhou Medical University","highestDevelopmentStatusID":"8","companyTruncated":"Techpool Bio-Pharma \/ The First Affiliated Hospital of Guangzhou Medical University"},{"orgOrder":0,"company":"Bharat Serums & Vaccines ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Urinastatin","moa":"enzyme inhibitors: antihyperlipidemics (HMG-CoA inhibitors)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bharat Serums & Vaccines ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bharat Serums & Vaccines ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bharat Serums & Vaccines ltd \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Urinastatin

    Menu

    Urinastatin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Bharat Serums & Vaccines ltd

                            India arrow
                            OTS 2025
                            Not Confirmed

                            Bharat Serums & Vaccines ltd

                            India arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Urinastatin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bharat Serums to assess sepsis drug Ulinastatin for Covid-19

                            Details : The trial will involve approximately 120 patients who have mild to moderate symptoms of acute ARDS. The drug is expected to improve recovery time and also mitigate mortality rates.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 09, 2020

                            Lead Product(s) : Urinastatin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Techpool Bio-Pharma

                            China arrow
                            OTS 2025
                            Not Confirmed

                            Techpool Bio-Pharma

                            China arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Urinastatin

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : The First Affiliated Hospital of Guangzhou Medical University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Safety and Dose Response Relationship of Ulinastatin for Acute Respiratory Distress Syndrome(ARDS)

                            Details : Ulinastatin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Respiratory Distress Syndrome.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 09, 2016

                            Lead Product(s) : Urinastatin

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : The First Affiliated Hospital of Guangzhou Medical University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Peking Union Medical College Hospital

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Peking Union Medical College Hospital

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Urinastatin

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase IV

                            Sponsor : Techpool Bio-Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ulinastatin Treatment in Adult Patients With Sepsis and Septic Shock in China

                            Details : Ulinastatin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Shock, Septic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 06, 2016

                            Lead Product(s) : Urinastatin

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase IV

                            Sponsor : Techpool Bio-Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Techpool Bio-Pharma

                            China arrow
                            OTS 2025
                            Not Confirmed

                            Techpool Bio-Pharma

                            China arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Urinastatin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Sponsor : Shanghai Children's Medical Center | Guangzhou Women and Children's Medical Center | Guangzhou General Hospital of Guangzhou Military Command | Nanjing Children's Hospital | Children's Hospital of Fudan University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ulinastatin Injection in in Pediatric Patients Undergoing Open Heart Surgery

                            Details : Ulinastatin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Heart Defects, Congenital.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 19, 2015

                            Lead Product(s) : Urinastatin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Shanghai Children's Medical Center | Guangzhou Women and Children's Medical Center | Guangzhou General Hospital of Guangzhou Military Command | Nanjing Children's Hospital | Children's Hospital of Fudan University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Techpool Bio-Pharma

                            China arrow
                            OTS 2025
                            Not Confirmed

                            Techpool Bio-Pharma

                            China arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Urinastatin

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase IV

                            Sponsor : Peking Union Medical College Hospital | Wuhan Union Hospital | First Clinical College of Harbin Medical University | The First Affiliated Hospital with Nanjing Medical University | West China Hospital | First Affiliated Hospital, Sun Yat-Sen University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ulinastatin in Severe Acute Pancreatitis

                            Details : Ulinastatin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pancreatitis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 28, 2010

                            Lead Product(s) : Urinastatin

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase IV

                            Sponsor : Peking Union Medical College Hospital | Wuhan Union Hospital | First Clinical College of Harbin Medical University | The First Affiliated Hospital with Nanjing Medical University | West China Hospital | First Affiliated Hospital, Sun Yat-Sen University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth